Literature DB >> 27308520

Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors.

Cyril H Benes1.   

Abstract

We have performed a study using cell lines established from biopsies of clinically resistant non-small cell lung cancers with the aim of discovering therapeutic strategies to overcome acquired resistance. Our results indicate that pharmacological assessment of tumor material might efficiently complement genetic profiling in the future path toward personalized medicine.

Entities:  

Keywords:  cancer; drug resistance; personalized medicine; tyrosine kinase inhibitor

Year:  2015        PMID： 27308520      PMCID： PMC4905366          DOI： 10.1080/23723556.2014.999504

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Authors:  Adam S Crystal; Alice T Shaw; Lecia V Sequist; Luc Friboulet; Matthew J Niederst; Elizabeth L Lockerman; Rosa L Frias; Justin F Gainor; Arnaud Amzallag; Patricia Greninger; Dana Lee; Anuj Kalsy; Maria Gomez-Caraballo; Leila Elamine; Emily Howe; Wooyoung Hur; Eugene Lifshits; Hayley E Robinson; Ryohei Katayama; Anthony C Faber; Mark M Awad; Sridhar Ramaswamy; Mari Mino-Kenudson; A John Iafrate; Cyril H Benes; Jeffrey A Engelman
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

2.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

3.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.

Authors:  Xuefeng Liu; Virginie Ory; Sandra Chapman; Hang Yuan; Chris Albanese; Bhaskar Kallakury; Olga A Timofeeva; Caitlin Nealon; Aleksandra Dakic; Vera Simic; Bassem R Haddad; Johng S Rhim; Anatoly Dritschilo; Anna Riegel; Alison McBride; Richard Schlegel
Journal:  Am J Pathol       Date:  2011-12-18       Impact factor: 4.307

4.  Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

Authors:  Akira Inoue; Takuji Suzuki; Tatsuro Fukuhara; Makoto Maemondo; Yuichiro Kimura; Naoto Morikawa; Hiroshi Watanabe; Yasuo Saijo; Toshihiro Nukiwa
Journal:  J Clin Oncol       Date:  2006-06-19       Impact factor: 44.544

Review 5.  Understanding resistance to targeted cancer drugs through loss of function genetic screens.

Authors:  Katrien Berns; René Bernards
Journal:  Drug Resist Updat       Date:  2012-11-09       Impact factor: 18.500

6.  A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Authors:  Sreenath V Sharma; Diana Y Lee; Bihua Li; Margaret P Quinlan; Fumiyuki Takahashi; Shyamala Maheswaran; Ultan McDermott; Nancy Azizian; Lee Zou; Michael A Fischbach; Kwok-Kin Wong; Kathleyn Brandstetter; Ben Wittner; Sridhar Ramaswamy; Marie Classon; Jeff Settleman
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

7.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

Review 8.  Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.

Authors:  Matthew J Niederst; Jeffrey A Engelman
Journal:  Sci Signal       Date:  2013-09-24       Impact factor: 8.192

Review 9.  Acquired resistance to tyrosine kinase inhibitors during cancer therapy.

Authors:  Jeffrey A Engelman; Jeffrey Settleman
Journal:  Curr Opin Genet Dev       Date:  2008-03-05       Impact factor: 5.578

10.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

Authors:  Cory M Johannessen; Laura A Johnson; Federica Piccioni; Aisha Townes; Dennie T Frederick; Melanie K Donahue; Rajiv Narayan; Keith T Flaherty; Jennifer A Wargo; David E Root; Levi A Garraway
Journal:  Nature       Date:  2013-11-03       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.